• In March 2026, Synchrony Financial announced a partnership with Figo Pet Insurance that lets pet owners use CareCredit to pay upfront vet bills and receive approved insurance reimbursements directly as credits to their CareCredit accounts.
• This integration expands CareCredit’s pet insurance reimbursement ecosystem to more than 1.20 billion insured policyholders across Figo, Pets Best, and Pumpkin, simplifying veterinary payments for customers and clinics.
• Next, we’ll examine how this expanded pet-health reimbursement ecosystem could influence Synchrony’s investment narrative around health and wellness financing.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Synchrony Financial Investment Narrative Recap

To own Synchrony, you generally need to believe its partner-centric model can still grow receivables and earnings despite credit tightening, rising competition, and regulatory pressure. The Figo partnership modestly supports the near term health and wellness growth catalyst by deepening CareCredit’s role in pet care, but it does not materially change the key short term risk that lower purchase volumes and elevated payment rates could limit loan growth and revenue.

The Figo announcement ties most closely to Synchrony’s broader push into health, wellness, and pet financing, where CareCredit is being embedded across more platforms such as Planet DDS in orthodontics and Weave in dental practices. Together, these integrations point to a more interconnected CareCredit ecosystem across medical and pet care, which may help diversify Synchrony’s revenue away from its highly concentrated retail partner base over time.

Yet, beneath this growth story, investors should be aware of the risk that flat purchase volumes and rising credit competition could still...

Synchrony Financial's narrative projects $16.5 billion revenue and $3.3 billion earnings by 2028. This requires 21.7% yearly revenue growth and about a $0.1 billion earnings increase from $3.2 billion today.

Uncover how Synchrony Financial's forecasts yield a $90.26 fair value, a 32% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts paint a far more cautious picture, assuming revenue of about US$15.9 billion and flat US$2.9 billion earnings, so compared with the Figo news and credit volume risks you have just read about, it is worth remembering that thoughtful investors can see the same company very differently and that new developments like this partnership may eventually shift both the optimistic and the more pessimistic views.

Explore 8 other fair value estimates on Synchrony Financial - why the stock might be worth just $74.31!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Synchrony Financial research is our analysis highlighting 6 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Synchrony Financial research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Synchrony Financial's overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.